Search

everythinglearnresearchcommunity

for

Search:↓

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Male pattern baldness may predict prostate cancer risk.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Different prostate cancer treatments have similar risks of secondary cancers and related mortality when considering patient age and smoking history.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Long-term diabetes is linked to lower prostate cancer risk.